FI970579A0 - Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin - Google Patents

Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin

Info

Publication number
FI970579A0
FI970579A0 FI970579A FI970579A FI970579A0 FI 970579 A0 FI970579 A0 FI 970579A0 FI 970579 A FI970579 A FI 970579A FI 970579 A FI970579 A FI 970579A FI 970579 A0 FI970579 A0 FI 970579A0
Authority
FI
Finland
Prior art keywords
glutathione peroxidase
andenovirus
gene encoding
encoding glutathione
relates
Prior art date
Application number
FI970579A
Other languages
English (en)
Swedish (sv)
Other versions
FI970579A (fi
Inventor
Martine Barkats
Jacques Mallet
Frederic Revah
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI970579A publication Critical patent/FI970579A/fi
Publication of FI970579A0 publication Critical patent/FI970579A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
FI970579A 1994-08-12 1997-02-11 Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin FI970579A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9409982A FR2723588B1 (fr) 1994-08-12 1994-08-12 Adenovirus comprenant un gene codant pour la glutathion peroxydase
PCT/FR1995/001002 WO1996005320A1 (fr) 1994-08-12 1995-07-26 Adenovirus comprenant un gene codant pour la glutathion peroxydase

Publications (2)

Publication Number Publication Date
FI970579A FI970579A (fi) 1997-02-11
FI970579A0 true FI970579A0 (fi) 1997-02-11

Family

ID=9466290

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970579A FI970579A0 (fi) 1994-08-12 1997-02-11 Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin

Country Status (14)

Country Link
US (2) US20010029249A1 (fi)
EP (1) EP0775213B1 (fi)
JP (1) JPH10504193A (fi)
AT (1) ATE293700T1 (fi)
AU (1) AU710727B2 (fi)
CA (1) CA2197235C (fi)
DE (1) DE69534165T2 (fi)
FI (1) FI970579A0 (fi)
FR (1) FR2723588B1 (fi)
IL (1) IL114904A0 (fi)
MX (1) MX9700851A (fi)
NO (1) NO970282D0 (fi)
WO (1) WO1996005320A1 (fi)
ZA (1) ZA956678B (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6200799B1 (en) * 1997-06-03 2001-03-13 University Of Lausanne Somatic gene therapy to suppress secondary cataract formation following eye surgery
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CN1433470A (zh) 1999-10-29 2003-07-30 启龙股份公司 奈瑟球菌的抗原性肽
DK1248647T3 (da) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
NZ533428A (en) 2001-12-12 2008-03-28 Chiron Srl Immunisation against chlamydia trachomatis
EP1474158B1 (en) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1736541B1 (en) 2004-03-29 2013-01-23 Galpharma Co., Ltd. Novel modified galectin 9 protein and use thereof
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
DK3161129T3 (da) * 2014-06-27 2019-11-04 Angiocrine Bioscience Inc Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007541A1 (en) * 1987-04-01 1988-10-06 Chiron Corporation Polynucleotide construct encoding a polypeptide substantially similar to human glutathione peroxidase
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
JPH0327289A (ja) 1989-06-22 1991-02-05 Toyo Jozo Co Ltd 新規な血漿型グルタチオン・パーオキシダーゼ遺伝子およびその用途
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
AU7019494A (en) 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system

Also Published As

Publication number Publication date
US7241591B2 (en) 2007-07-10
NO970282L (no) 1997-01-22
US20010029249A1 (en) 2001-10-11
FI970579A (fi) 1997-02-11
AU3082695A (en) 1996-03-07
CA2197235A1 (fr) 1996-02-22
ZA956678B (en) 1996-03-20
US20040175363A1 (en) 2004-09-09
DE69534165D1 (de) 2005-05-25
ATE293700T1 (de) 2005-05-15
DE69534165T2 (de) 2006-03-09
CA2197235C (fr) 2010-07-20
JPH10504193A (ja) 1998-04-28
EP0775213B1 (fr) 2005-04-20
FR2723588B1 (fr) 1996-09-20
AU710727B2 (en) 1999-09-30
WO1996005320A1 (fr) 1996-02-22
MX9700851A (es) 1997-04-30
NO970282D0 (no) 1997-01-22
FR2723588A1 (fr) 1996-02-16
EP0775213A1 (fr) 1997-05-28
IL114904A0 (en) 1995-12-08

Similar Documents

Publication Publication Date Title
FI970579A0 (fi) Andenovirus, joka käsittää glutationiperoksidaasia koodittavan geenin
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
ATE413386T1 (de) Ppar-gamma modulatoren
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
DE69905170T2 (de) Thiazolopyrimidinderivate
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
IL138665A0 (en) Peptide factor
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
HUP0002985A2 (hu) Glicirrizinsavat és legalább egy antivirális hatású proteint tartalmazó vírusellenes gyógyszerkészítmény
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
SE9802937D0 (sv) Novel compounds
NO981019D0 (no) Deodoriserende preparater inneholdende kationiske biopolymerer, aluminiumklorhydrat og esteraseinhibitorer
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
ATE28188T1 (de) Antikonvulsive mittel.
ATE305517T1 (de) Neurotrypsin
PE20399A1 (es) Muteina ob
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
TR200000916T2 (tr) İkameli piperidin türevleri.

Legal Events

Date Code Title Description
MA Patent expired